JACOBIO PHARMA LTD. SUCCESSFULLY LISTED ON HKEX
Latest Update:
21 st December, 2020

On 21 December 2020, Jacobio Pharma Ltd. (stock code: 1167.HK) was listed on the main board of the Stock Exchange of Hong Kong Limited (" THE Stock Exchange of Hong Kong "). Porda Havas served as the financial pr consultant for the company's IPO in Hong Kong.

The first day of trading opened at HK $15.98, up 14.14% from the OFFER price of HK $14.

Goldman Sachs (Asia) Limited and China International Capital Hong Kong Securities Limited are the joint sponsors, joint global coordinators, joint bookrunners and joint lead managers of the offering. The company's shareholders are comprised of global and domestic institutional investors as well as biotech focused investment funds, including Qiming Ventures, Hillhouse Capital, Eli Lilly Asia Fund and BioEngine.

Founded in July 2015, Jacobio Pharma Ltd. is a clinical stage pharmaceutical company focused on the independent discovery and development of innovative oncology therapies. The company is an explorer in the development of clinical-stage small molecule drug candidates that bind to allosteric sites to regulate enzymes in response to a lack of readily available pockets that allow drug binding.

Selecting important but often overlooked targets, We remain committed to addressing unmet patient needs and developing novel "first of all" therapies. Company has established an integrated small molecular cancer drug discovery platform, the platform has a proprietary innovative drug discovery and design technology, and related key cell signaling pathways (especially the combination of target allosteric site) drug targets in the professional technology, make the company in a "nothing medicinal into successful medicinal" the forefront of this new concept.

Several drug candidates in the company's discovery platform show promising potential and are among the first to enter the market globally in their respective drug categories. For example, the company has focused on SHP2 since its inception and has developed a second SHP2 inhibitor that has been approved for clinical development by the U.S. FDA in IND with its proprietary drug design platform focused on allosteric binding sites

About Jacobio Pharma Ltd.

Jacobio Pharma Is a clinical stage pharmaceutical company focused on the indigenous discovery and development of innovative oncology therapies. The company is an explorer in the development of clinical-stage small molecule drug candidates that bind to allosteric sites to regulate enzymes in response to a lack of readily available pockets that allow drug binding. Division, pharmaceutical industry with in drug discovery and development of patent technology and professional technology found in the research and development innovation drug candidates, the company has two clinical stages of SHP2 inhibitors projects as well as the leading KRAS inhibitors, its rich in research projects also include in the early stages of targeting a variety of other key signaling pathways of drug candidates, Could be one of the first products to enter the market globally in this corresponding drug class. The company has entered into a strategic partnership with AbbVie for the global development and commercialization of SHP2 inhibitors. The company will continue to actively cooperate with leading multinational companies, while establishing manufacturing and commercialization capabilities in China, and seize the global market opportunities to provide effective and innovative therapies for cancer patients worldwide.

Latest Update:
21 st December, 2020